Distinct representation of muscle weakness in QMG and MG-ADL

Affiliations

¹ Department of Neurology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands. Electronic address: rhpdemeel@lumc.nl.
² Department of Neurology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands.

Comment

Robert Henri Pasquale de Meel et al. Lancet Neurol. 2018 Mar.

. 2018 Mar;17(3):204-205.

doi: 10.1016/S1474-4422(18)30037-1.

¹ Department of Neurology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands. Electronic address: rhpdemeel@lumc.nl.
² Department of Neurology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands.

No abstract available

Comment in

Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply.
Howard JF Jr, O'Brien F, Wang JJ. Howard JF Jr, et al. Lancet Neurol. 2018 Mar;17(3):205-206. doi: 10.1016/S1474-4422(18)30036-X. Lancet Neurol. 2018. PMID: 29452680 No abstract available.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.